UAB 1033/TBCRC 018: A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201) in Combination with Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Grant

Awarded By

Total Award Amount

  • 27200.00

    • Direct Costs

  • 24727.00

    • Sponsor Award Id

    • Contributor

  • Lisle Nabell M.D.   Investigator